Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Human Genome Sciences, Inc. (HGSI) -- Ignore unavailable to you. Want to Upgrade?

To: John Lacelle who wrote (618)	6/7/2001 11:04:30 AM
From: Harold Engstrom	Read Replies (1) \| Respond to of 1127

John, You should do some research, even cursory research, on genomics and the companies in the field. Also, do some research on the background of the posters who comment on genomics and the companies in the field. There are quite a few people here at SI that know their stuff and then there are those who do not know their stuff at all. Focusing on a price/sales ratio for a company like this is pretty silly. OTOH, it is difficult to fix a value on biotech companies and especially genomics companies. I eyeball HGSI at a value of about $50/share with tremendous upside potential. This is based on their cash position, partnerships, pipeline and infrastructure. Shorting HGSI might work at this price level. I wouldn't do it myself... but, I do think it is overvalued based on publicly available information. Note that HGSI is one of those companies that is probably part of any large, diversified portfolio with a biopharm component: genomics has a few companies in it and HGSI, along with INCY, looks like it will be a winner in the end. H